Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate 1: Family Office Investing in Personal Medicine Diagnostics and Digital Health

22 Jun

A private investment firm led by seasoned entrepreneur and venture capitalist is looking to make venture investments in emerging fast growth projects. Typical equity investments ranges from $500,000 to $3 million per deal. The firm will invest in companies across the United States and Canada.

Currently the firm is most interested in areas of personal medicine diagnostics, particularly in genomics and proteomics. Other areas of high interest include, digital health, platform technologies, nutrition, clean environment, and much more selectively drug development and medical devices. The firm has experience in immunology and is more familiar with vaccine and antibody based technologies. The firm is open in terms of indication and considers orphan indications as well but requires strong data and a clear pathway to exit.

The firm invests in privately held companies and will both lead or co-invest. The firm looks to take a board seat in some of its portfolio companies though it is not a requirement. The firm looks for smart and passionate management teams with high levels of experience in the field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: European-based Evergreen Fund Investing in Early-stage Therapeutics

22 Jun

An evergreen life science venture fund located in Copenhagen, Denmark, established in the autumn of 2009 and wholly owned by a large European corporate currently has DKK 1.6 billion in AUM. The firm has an annual investment capacity of approximately 350 – 400m DKK. Investments are typically around €10 million with reserves to follow, and the firm prefers to take above 10% ownership. The firm invests primarily in Europe and in the USA.

The firm invests exclusively in life sciences, focusing on pharmaceuticals. The firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The firm is open to opportunities in all therapeutic areas and indications. The firm primarily invest in clinical projects and companies with new technology platforms and are particularly interested in specialist product opportunities.

The firm is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US the firm prefers to syndicate with well-established VC investors specialized in life sciences. The firm expects to be actively in communication with management and represented on the supervisory board of portfolio companies. The firm is seeking experienced and capable management teams that are committed to resolving the unmet medical needs. Other requirements are a well-defined plan, a strong and durable patent protection, and a sound understanding of the relevant markets and their regulatory frameworks.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Taiwan-based CVC Investing in Therapeutics and Digital Health

22 Jun

A corporate venture of a publicly listed Taiwanese pharmaceutical company now focuses on strategic investments and add-on acquisition for its portfolio companies. Typical allocation size ranges from US$5-20 million. The firm is currently seeking opportunities in Asia and the US.

The CVC is investing strategically for its portfolio companies in select sectors. Within therapeutics, the firm considers small molecules, biologics, antibody-drug conjugates, and gene therapies in oncology. The firm also considers CNS, pain, cardiovascular and metabolic disease, and infectious diseases. The firm typically invests in late preclinical projects to phase 1 trial. Within medical technologies, the firm is interested in innovative digital health innovations.

The firm is looking for experienced management teams with strong scientific expertise and management skills. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Subsidiary Fund of Health Insurance Corporate Investing in Consumer Health Solutions

22 Jun

A wholly owned subsidiary of an established private health insurance company seeks to investment in technologies that are a strategic fit with members of the network. The firm is flexible in terms of investment sizes and considers an array of capital structures including equity, convertible note, debt, and others. The firm typically co-invests with other investors but is open to leading a financing round. The firm is currently seeking new opportunities from across the US, while non-US opportunities may also be considered.

The firm is focused on opportunities in the following areas: Accountable Care Organizations, Consumer Solutions; Health Information Technology; and Behavioral Health. Potential examples may include consumer-facing patient engagement software, behavioral health technology, telemedicine, and B2B solutions that help healthcare organizations with decision making and financial planning. The firm is stage agnostic and would consider from pre-revenue to commercial-stage companies. Historically the firm has invested in patient monitoring system, EHR aggregation and analytics, and mobile health information platform.

The firm is seeking experienced, competent teams with disruptive innovations that are a strategic fit with its members. After investment, the firm typically request a board seat or at least an observer position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 1: US Firm Works with China Partner to Invest in Disruptive Life Science Technologies

15 Jun

A venture capital firm based in Palo Alto, CA is looking for early stage life science opportunities. The firm also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in a total of 13 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and healthcare IT, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Venture Firm Makes Seed and Series A Investments in Medtech and Digital Health

15 Jun

A venture capital firm based in Solana Beach, CA provides seed funding to very early stage companies and also invests in Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: East Coast Fund Makes Multi-Stage Medtech and Healthcare IT Deals

15 Jun

A venture capital firm based in New York City is focused on companies in the healthcare field with a preference for Medtech, Healthcare IT, and Consumer Health. The firm is currently investing out of their second fund, and hopes to make 2-3 investments out of it this coming year. The firm invests in all stages of companies, from Series A to Series G.

The firm considers themselves opportunistic within the healthcare field when looking for investments. The firm focuses on three major categories: Medtech (Devices and Diagnostics), Healthcare IT, and Consumer Health and is opportunistic within all three. The firm tends to prefer investments within the medtech space, a space they’re more experienced in. While opportunistic, the firm prefers opportunities in the hearing, vision, heart failure, neuromodulation, and diabetes due to previous experience in these sectors. Regarding Healthcare IT interests, the firm prefers opportunities targeted towards large audiences such as healthcare systems or large patient populations.

The firm wants to see a strong CEO and Board when making investments. The firm invests in both pre-revenue and post-revenue companies. The firm typically invests alongside a syndicate of investors, but is looking to lead or co-lead more investments in their second fund. When leading or co-leading the firm requires a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com